Zacks Research Has Negative Forecast for AGIO Q3 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Research analysts at Zacks Research reduced their Q3 2025 earnings estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn ($1.80) per share for the quarter, down from their previous forecast of ($1.79). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($4.87) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.79) EPS, FY2025 earnings at ($6.99) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.57) EPS, Q3 2026 earnings at ($1.52) EPS and FY2026 earnings at ($5.95) EPS.

A number of other equities analysts also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 16th. Scotiabank assumed coverage on shares of Agios Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $51.00 price target on the stock. Finally, Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $52.00.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $45.08 on Friday. The company has a market cap of $2.56 billion, a P/E ratio of -7.13 and a beta of 0.75. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $53.28. The firm has a fifty day moving average of $44.64 and a two-hundred day moving average of $41.46.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.51) EPS.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Nordea Investment Management AB boosted its stake in shares of Agios Pharmaceuticals by 13.0% during the 1st quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock worth $7,824,000 after purchasing an additional 30,764 shares during the last quarter. Caxton Associates LP acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth about $1,087,000. Vanguard Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock worth $123,096,000 after purchasing an additional 59,851 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Agios Pharmaceuticals by 87.3% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock worth $29,245,000 after purchasing an additional 316,100 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Agios Pharmaceuticals by 23.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after purchasing an additional 388,381 shares during the last quarter.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Brian Goff sold 11,091 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.